

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number
WO 2003/086371 A3

(51) International Patent Classification⁷: **A61K 31/00**,
31/4178, 31/437, 31/42, 31/421, 31/422, 31/426, A61P
1/16, 7/02, 9/00, 25/28, 25/00, 37/06, G01N 33/80

(74) Agents: **LUMB, J., Trevor** et al.; Pfizer Inc., 201 Tabor
Road, Morris Plains, NJ 07950 (US).

(21) International Application Number:
PCT/IB2003/001310

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 3 April 2003 (03.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:
60/372,364 12 April 2002 (12.04.2002) US

(71) Applicant (*for JP only*): **PFIZER PHARMACEUTI-
CALS INC.** [JP/JP]; Mitsui Building, 1-1, Nishi-shinjuku
2-chome, Shinjuku-ku, Tokyo 163-0461 (JP).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(71) Applicant (*for all designated States except JP, US*):
PFIZER INC. [US/US]; 235 East 42nd Street, New York,
NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **SHIMOJO, Masato**
[JP/JP]; Pfizer Global Research and Development, Nagoya
Laboratoires Pfizer Inc., 5-2 Taketoyo, Aichi 470-2393
(JP). **TANIGUCHI, Kana** [JP/JP]; Pfizer Global Research
& Development, Nagoya Laboratories Pfizer Inc., 5-2
Takeoyo, Aichi 470-2393 (JP).

(88) Date of publication of the international search report:
3 June 2004

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES

(57) Abstract: The present invention relates to the use of an EP4 receptor ligand in the manufacture of a medicament for the treat-
ment of IL-6 involved diseases. Also relates to the assay comprising: culturing peripheral whole blood with a test compound; and
determining the effect of the compound on PGE2-induced whole blood cells activation.

WO 2003/086371 A3